Champions Oncology's (NASDAQ:CSBR) investors will be pleased with their respectable 47% return over the last year
Stock Performance Overview: Champions Oncology, Inc. has experienced a 23% decline in share price over the past month, but a significant 47% increase over the last year indicates strong long-term performance and positive sentiment around the company.
Financial Metrics and Recommendations: The company reported a shift from loss to profit with a year-on-year revenue growth of 19%, although there is one warning sign identified; potential investors are advised to consider insider buying trends and other market factors before making investment decisions.
Trade with 70% Backtested Accuracy
Analyst Views on CSBR
About CSBR
About the author
Champions Oncology (CSBR) Earnings Transcript
Key Stocks Reporting Earnings This Week: Micron, FuelCell, Carnival, and Others
Earnings Reports Schedule: This week features earnings reports from various companies, including homebuilders, apparel brands, and tech firms, with notable reports from Micron Technology and Nike.
Key Earnings Dates: Major companies reporting include Navan, Ark Restaurants, and Champions Oncology on Monday; Organigram and Duluth Holdings on Tuesday; and a heavy slate on Wednesday with Jabil, General Mills, and Micron.
Investor Focus: Investors are particularly interested in Micron's performance, with expectations of strong earnings driven by high bandwidth memory sales for AI chips.
End of Week Reports: The week will conclude with Carnival Corp and other companies like Paychex and Conagra Brands reporting before Friday's market open.
Transcript of Champions Oncology, Inc. (CSBR) Earnings Call for Q1 2026
Earnings Call Overview: Champions Oncology held its Q1 2026 earnings call on September 15, 2025, led by CEO Rob Brainin and CFO David Miller, discussing the company's financial performance and strategic direction.
Financial Performance: The company reported $14 million in revenue for Q1 2026, marking a recovery from previous quarter challenges, with growth primarily driven by its TOS business.
Champions Oncology aims for continuous revenue increase and improved margins as radiopharmaceuticals and data platforms progress.
Management Insights: CEO Rob Brainin highlighted a strong rebound in fiscal 2025 with record revenue of $14 million, driven by the TOS business and emerging data platform, while emphasizing the importance of strategic execution for long-term growth.
Financial Performance: The company reported a loss from operations of $0.5 million, with a gross margin decline to 43% due to increased outsourcing costs, but anticipates margin improvement as radiolabeling processes are internalized.
Outlook and Guidance: Management expects sequential revenue growth and margin expansion in Q2, maintaining a confident outlook despite challenges in the macro environment, particularly in biotech funding.
Analyst Sentiment: Analysts expressed cautious optimism regarding the data business and revenue growth, while management's tone remained confident, focusing on foundational strength and strategic continuity under the new CEO.
Champions Oncology Reports Non-GAAP EPS of $0.02, Exceeding Estimates by $0.03; Revenue of $14M Surpasses Expectations by $0.49M
Earnings Performance: Champions Oncology reported a Q1 Non-GAAP EPS of $0.02, exceeding expectations by $0.03.
Revenue Details: The company generated revenue of $14 million, reflecting a slight decline of 0.4% year-over-year, but still beating estimates by $0.49 million.
4 Biotech Stocks Experiencing Decline: Momentum Scores Diminishing in the Last Week
Biotech Stocks Momentum Decline: Several biotech stocks have experienced significant declines in their Momentum scores over the past week, indicating a loss of strength in the sector.
Key Companies Affected: Notable companies like Capricor Therapeutics, Lava Therapeutics, Alaunos Therapeutics, and Champions Oncology have all reported drops in their Momentum scores due to various factors, including regulatory setbacks, financial losses, and downgrades from analysts.
Champions Oncology (CSBR) Earnings Transcript
Key Stocks Reporting Earnings This Week: Micron, FuelCell, Carnival, and Others
Earnings Reports Schedule: This week features earnings reports from various companies, including homebuilders, apparel brands, and tech firms, with notable reports from Micron Technology and Nike.
Key Earnings Dates: Major companies reporting include Navan, Ark Restaurants, and Champions Oncology on Monday; Organigram and Duluth Holdings on Tuesday; and a heavy slate on Wednesday with Jabil, General Mills, and Micron.
Investor Focus: Investors are particularly interested in Micron's performance, with expectations of strong earnings driven by high bandwidth memory sales for AI chips.
End of Week Reports: The week will conclude with Carnival Corp and other companies like Paychex and Conagra Brands reporting before Friday's market open.
Transcript of Champions Oncology, Inc. (CSBR) Earnings Call for Q1 2026
Earnings Call Overview: Champions Oncology held its Q1 2026 earnings call on September 15, 2025, led by CEO Rob Brainin and CFO David Miller, discussing the company's financial performance and strategic direction.
Financial Performance: The company reported $14 million in revenue for Q1 2026, marking a recovery from previous quarter challenges, with growth primarily driven by its TOS business.
Champions Oncology aims for continuous revenue increase and improved margins as radiopharmaceuticals and data platforms progress.
Management Insights: CEO Rob Brainin highlighted a strong rebound in fiscal 2025 with record revenue of $14 million, driven by the TOS business and emerging data platform, while emphasizing the importance of strategic execution for long-term growth.
Financial Performance: The company reported a loss from operations of $0.5 million, with a gross margin decline to 43% due to increased outsourcing costs, but anticipates margin improvement as radiolabeling processes are internalized.
Outlook and Guidance: Management expects sequential revenue growth and margin expansion in Q2, maintaining a confident outlook despite challenges in the macro environment, particularly in biotech funding.
Analyst Sentiment: Analysts expressed cautious optimism regarding the data business and revenue growth, while management's tone remained confident, focusing on foundational strength and strategic continuity under the new CEO.
Champions Oncology Reports Non-GAAP EPS of $0.02, Exceeding Estimates by $0.03; Revenue of $14M Surpasses Expectations by $0.49M
Earnings Performance: Champions Oncology reported a Q1 Non-GAAP EPS of $0.02, exceeding expectations by $0.03.
Revenue Details: The company generated revenue of $14 million, reflecting a slight decline of 0.4% year-over-year, but still beating estimates by $0.49 million.
4 Biotech Stocks Experiencing Decline: Momentum Scores Diminishing in the Last Week
Biotech Stocks Momentum Decline: Several biotech stocks have experienced significant declines in their Momentum scores over the past week, indicating a loss of strength in the sector.
Key Companies Affected: Notable companies like Capricor Therapeutics, Lava Therapeutics, Alaunos Therapeutics, and Champions Oncology have all reported drops in their Momentum scores due to various factors, including regulatory setbacks, financial losses, and downgrades from analysts.
